Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You know what I say? MS is BS.
Why specifically mention three trials starting up in 2017? Don't get it, do you? Biotech CEO say whatever they want.
For a couple of years now this has been going on, kind of funny. I'm in again for the ride up, however brief
in the end, it would be a lot harder to do what they've been doing for so long if management were not so incompetent, it's like they set themselves up.
He doesn't know anything until a large number of patients confirms what he thinks he knows. Period.
Today the price was so low that it reminded me of my original pre-split entry and I started a new position, nostalgically.
at this price? interesting.
lots of volume
Tutes still having trouble picking up shares due to the fact that no one's selling?
AH 2.97. Should be interesting at open, if market is red.
for retail stocks like this usually are. The trick--most of the time--is to know when to cut your losses.
Missling is just like any other Biotech CEO: he'll take money when he can get it. Don't know how he managed to convince the board that he was any different. i mean, he didn't really do anything to make us think so. In the end--like most investments--we made ourselves think so.
Thanks, Tom. I do consider your posts when I buy or sell shares. I sold half of my position at 3.60. Almost bought it back today--had a limit order in @3.00--but then cancelled it. If general market conditions don't cooperate over the next few days (and congress continues to twiddle their thumbs) I think we go lower, around your 2.70 target zone.
where's this headed? How low? Not necessarily anemic volume.
a bunch of Jan. 5 and 7.50 calls down the drain. One of my biggest losses last year was AVXL calls, betting on data at a conference. Funny how hope extends itself in time, seemingly costing less.
Couldnt agree more, though some are saying no one's selling, it's hard to buy, etc. Funny how that works.
Well, a lot of this has to be with trust, as far as I'm concerned. Of course, there's manipulation, but in biotech there's usually a reason for it: shorts know who to pick on. Look at SGYP, for example, which has had terrible management, among other problems.
no, tom, there wasn't. But every time Anavex tweets one of these "new" indication prs, or mouse studies, he usually makes a snide remark. One of them, if I remember correctly, was directed toward 2-73's ability to cure all CNS diseases.
hell of a bounce. Street is fighting to get in, but, of course, no one is selling.
Just might add, as of now, volume is higher than average. Hmmm.
I expect the drop is due to the patent fluff pr that Adam Feuerstein has criticized more than once. True, fluff. No meaningful trials have started up. This is really getting pathetic.
c'mon, be honest: how many of you, seeing today's pr, thought AVXL would be up?
FI, you make perfect sense. Logical, sensible conclusions about Ph2/3 AD trial.
Nothing--ever--happens at conferences.
yah, someone, the retail investor, confuses form with content. Perfectly understandable when hope is doing the thinking.
It never is. Neither in articles or tv reports. Why not? (Oh, btw, why doesn't the Street take AVXL seriously either? I forgot: the cabal.)
Noble Conference late January (what comes around, goes around, and we're still in the same place! Remember the last Noble conference? I do. Missling so enthusiastic about the PK/PD analysis. One year ago--and where has it gotten us? Misplaced enthusiasm, with a share price almost cut in half (as if the hot air had slowly been let out of his balloon of overpromise, sad). Can't wait to hear the rallying cry of the true believers. What words of hope will they cling to?
http://www.nobleconference.com/what.htm
Man, what an insightful post! (About as insightful as mine, I guess.)
AXON fail.
Be nice if AVXL put their molecule to the Ph2/3 test. Easy to sit back and say we have a winner when we don't compete.
I bet Pfizer is closing AD shop because they know they cannot compete with Anavex. What else could it be, board?
But we still have no idea if the drug works! (XENA, let's be honest: if we did--and I don't care what you say about the shorts--the share price would be a lot higher. My point: valuation is yet to be determined.)
Funny you should ask. Nine out of ten are green--again! This time it's SGYP in the red. No worries, I'm up, and expect it to go up, however little, over the next three weeks, before PDUFA. All is good in bioland, for now.
No you don't. Anavex has never released specific details of patient numbers. This board still cannot figure out what the charts mean. And apparently Anavex either; Hence, the genomic data-mining analysis. I'm not being negative. Just honest. People confuse the two.
And let's just cut to the chase: if the data were so clear, if you know exactly what the data indicate, demonstrating efficacy never before seen in an AD trial, the share price would reflect this fact. I've said this a million times, and I'll say it again: money isn't stupid. The problem is, nobody really knows, and nobody will really know until we have a large P h2/3 confirmatory trial, and the MC will increase only when market valuation adjusts to unambiguous data that demonstrate efficacy.
I'm considering it just because someone whom I consider a good biotech investor has opened a position recently, playing the run-up to Ph3 data. Whether or not it's a good AD drug is irrelevant. Just like AVXL two years ago. Miniscule mc (20m), with Ph2 data read-out. It was a no-brainer at the time. Now everything is much more complicated. Someone said a few days ago that they prefer playing the Ph1 data run-ups. I'm starting to understand why.
ok, he overpromised. I still remember the Catalyst checklist with the 2-73 updates at certain weeks. What happened to those?
So much ambiguity.
Not hardly. The only reason I might think about doing something so risky is to lower my cost basis, which is way too high. I guess that's what they call holding the bag. Feel good about my other positions, however, and 2017 wasn't without gains.